This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark
by Zacks Equity Research
Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.
Want To Retire Early? Learn the Intelligent Investing Secret - August 05, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
Grab These 4 High Earnings Yield Stocks for Solid Returns
by Zacks Equity Research
While comparing stocks, if other factors are similar, the stock with a higher earnings yield is considered undervalued.
Is a Surprise Coming for Bristol-Myers (BMY) This Earnings Season?
by Zacks Equity Research
Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.
Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.
3 Reasons Why Growth Investors Shouldn't Overlook Bristol Myers (BMY)
by Zacks Equity Research
Bristol Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.
Is a Beat in the Cards for Bristol-Myers' (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.
BMY vs. HZNP: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. HZNP: Which Stock Is the Better Value Option?
Signs That Your Trading Will Ruin Your Retirement - August 03, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - August 03, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Zacks.com featured highlights include: PHM, BMY, WERN, BBY and TSM
by Zacks Equity Research
Zacks.com featured highlights include: PHM, BMY, WERN, BBY and TSM
Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cronos (CRON) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q2 results.
Mylan (MYL) to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.
What's in the Cards for Regeneron's (REGN) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2020 results.
5 Solid Dividend Stocks That Promise Growth
by Sweta Killa
The dividend growth stocks have superior fundamentals that make dividend growth a quality and promising investment for the long term.
Amgen (AMGN) Stock Moves Lower Despite Q2 Earnings Beat
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for both earnings and sales. It maintains its previously-issued sales guidance while raising the earnings range. Stock dips.
Is a Beat in the Cards for Incyte's (INCY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports second-quarter 2020 results.
Want To Retire Early? Learn the Intelligent Investing Secret - July 28, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $58.05, moving +0.35% from the previous trading session.
What Lies Ahead for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
3 Top Dividend Stocks to Maximize Your Retirement Income - July 27, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?